Kiniksa Pharmaceuticals Q2 2025 Earnings Call Transcript: Key Highlights and Financial Results

Kiniksa Pharmaceuticals International reported Q2 2025 earnings, with CEO Sanj Patel providing an overview of the business. The company's Chief Commercial Officer, Ross Moat, discussed ARCALYST commercial execution, while CFO Mark Ragosa reviewed the financial results. The Q&A session will feature Sanj Patel, John Paolini, and Eben Tessari.

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) reported its second-quarter 2025 earnings on July 29, 2025, highlighting strong commercial performance and positive financial results. The company's CEO, Sanj K. Patel, provided an overview of the business, while Chief Commercial Officer Ross Moat discussed ARCALYST commercial execution and CFO Mark Ragosa reviewed the financial results. A Q&A session featuring Sanj Patel, John Paolini, and Eben Tessari is scheduled to follow.

Financial Highlights
Kiniksa reported total revenue of USD 156.8 million for Q2 2025, representing a 44% increase year-over-year (YoY) compared to USD 108.6 million in Q2 2024 [2]. Net income for the quarter was USD 17.8 million, a significant improvement over the net loss of USD 3.9 million in the same period last year [2]. Basic earnings per share from continuing operations were USD 0.24, up from a basic loss per share of USD 0.06 a year ago [2].

Commercial Performance
ARCALYST, the company's flagship product, generated USD 156.8 million in net product revenue for Q2 2025, marking a 52% YoY growth [3]. The product's success is attributed to expanding penetration among recurrent pericarditis patients and growth among both new and repeat prescribers. The company has raised its ARCALYST net sales guidance for 2025 to between USD 625 million and USD 640 million [3].

Clinical Trials and Pipeline
Kiniksa is also making progress in its clinical pipeline. The company has initiated the Phase 2 dose-focusing portion of the pivotal Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis, with data expected in the second half of 2026 [3]. Additionally, Kiniksa is conducting Investigational New Drug (IND)-enabling development activities for KPL-1161, an Fc-modified monoclonal antibody IL-1 receptor antagonist, with a target profile of quarterly subcutaneous (SC) dosing.

Financial Guidance and Cash Position
Kiniksa expects ARCALYST net product revenue of between USD 625 million and USD 640 million for 2025, compared to prior guidance of between USD 590 million and USD 605 million [3]. The company expects its current operating plan to remain cash flow positive on an annual basis. As of June 30, 2025, Kiniksa had USD 307.8 million in cash, cash equivalents, and short-term investments, with no debt [3].

Upcoming Events
Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, July 29, 2025, to discuss the second-quarter 2025 financial results and recent portfolio execution [3].

References:
[1] https://www.marketbeat.com/earnings/reports/2025-7-29-kiniksa-pharmaceuticals-ltd-stock/
[2] https://www.marketscreener.com/news/kiniksa-pharmaceuticals-international-plc-reports-earnings-results-for-the-second-quarter-and-six-m-ce7c5fd9d089f42c
[3] https://finance.yahoo.com/news/kiniksa-pharmaceuticals-reports-second-quarter-113000446.html